Showing results (121-130 of 268) with videos related to
Sort By:
Pageof 27
Cancer Research|June 1, 1986
Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartateT C Chan, M Markman, S Cleary, et al.Cancer Chemotherapy and Pharmacology|January 1, 1987
Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamoleM Markman, T C Chan, S Cleary, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1984
Totally implantable system for peritoneal accessC E Pfeifle, S B Howell, M Markman, et al.European Journal of Cancer (Oxford, England : 1990)|July 2, 2002
The cellular pharmacology of oxaliplatin resistanceM Mishima, G Samimi, A Kondo, et al.Cancer Research|December 15, 1994
Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell lineP Naredi, D D Heath, R E Enns, et al.Cancer Treatment Reports|September 1, 1982
High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose scheduleT N Campbell, S B Howell, C Pfeifle, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1988
Phase I/pharmacokinetic study of thioguanine administered as a 48-hour continuous intraperitoneal infusionS Zimm, S M Cleary, C N Horton, et al.Molecular Pharmacology|November 28, 2001
Identification of genes that mediate sensitivity to cisplatinH Niedner, R Christen, X Lin, et al.The Journal of Clinical Investigation|March 1, 1995
Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cellsP Naredi, D D Heath, R E Enns, et al.Cancer Drug Delivery|January 1, 1985
Maintenance of peritoneal catheter function by the intraperitoneal administration of 32% dextran 70C E Pfeifle, S B Howell, I S Abramson, et al.Pageof 27